There has been an increasing interest in the past decade in the role that endogenous vaso-active substances may play in the setiology of placental insufficiency and toxaemia of pregnancy. The posterior pituitary hormone, vasopressin, has received considerable attention and it has been demonstrated that levels of this hormone in blood and urine are higher in toxsemic women than in normal pregnant controls (Paterson 1960) . This is probably due, not to an increased production of hormone, but to a decrease in the blood levels of the inactivating enzyme, cystine aminopeptidase (Charvat & Holecek 1966) which allows an accumulation of the vasopressin. Serum levels of the enzyme can be used as an index of placental function (Josephides & Turkington 1967) .
A number of other vasopressor substances have been invoked, for example Hunter & Howard (1961) have claimed that 'hysterotonin' secreted by the decidua is involved, though other workers have failed to confirm this (Gomel & Hardwick 1966) . Uteroplacental ischemia may itself also lead to the production of vaso-active substances from the utero-foeto-placental unit (Berger & Cavanagh 1963 , Hodari 1967 . Placental amine oxidase is lower in toxaemic than normal women, and this could impair the metabolism of catecholamines and 5-hydroxytryptamine (see Southgate & Sandler 1968 for an excellent brief review). As well as an increased production of vaso-active substances, toxemic women show an increased sensitivity to these substances (Browne 1958 ).
If vaso-active substances acting in late pregnancy can cause foetal malnutrition or death, then it is possible that if such substances were released in excess during the period of embryogenesis, this could result in the production of congenital malformations. We have been interested for some time in the actions of endogenous substances, particularly 5-hydroxytryptamine (5-HT) when injected into pregnant animals. It has been demonstrated that 5-HT will interrupt pregnancy in mice if given during the preimplantation period (Lindsay et al. 1963) , will produce congenital malformations in the young if injected into mice or rats during the period of embryogenesis , Reddy et al. 1963 , Marley et al. 1967 ) and will cause foetal death if injected later in pregnancy in mice, rats and rabbits (see Marley et al. 1967 for references).
The mode of action of 5-HT in producing foetal death or malformations has been studied in detail , Marley et al. 1967 ) and we have suggested that its action is to reduce foetal nutrition mainly by reducing the uterine and placental blood flow.
The work has been extended to study other endogenous vaso-active substances and congenital malformations have been produced following injections of adrenaline, noradrenaline, isoprenaline, vasopressin and hypertensin (Sullivan 1965) . Not all of these substances act by the same mechanism, however: for example, 5-HT is inactive if injected into the feetus or amniotic sac, whereas vasopressin is about 1,000 times more active by this route than when given systemically to the mother.
Some indication that 5-HT may directly affect placental permeability has been obtained in the mouse (Honey et al. 1967) The Transfer of Drugs Across the Placenta Some good and comprehensive reviews concerning the placental transfer of drugs have appeared during the last ten years (Page 1957 , Hagerman & Villee 1960 , Marx 1961 , Moya & Thorndike 1962 , Schanker 1962 , Ginsburg & Jeacock 1964 , Moya & Smith 1965 , Nyhan & Lampert 1965 , Villee 1965 but, despite the large number of experimental observations which they list, all have lamented the lack of good quantitative data on which to base general theories. There have been few systematic studies, probably due to the technical difficulties involved. The data available consist mostly of isolated observations on different drugs, in different species, at different stages in the gestation period.
Nevertheless, there are sufficient facts to support the contention that transfer of drugs across the placenta can be considered in the same general terms as that across other biological membranes, e.g. the blood-brain barrier and the intestinal wall (Schanker 1962 , Brodie 1964 (After Smyth 1964) chorioallantoic placental membrane in different species and at different stages of pregnancy does not seem to impose alterations on permeability to drugs. The general processes involved (Fig 1) (Smyth 1964) are:
Active Transport and Facilitated Diffusion These processes, requiring energy, characterized by rates that are not proportional to concentration, often showing competition between molecules of related structure and probably depending on specific membrane carrier systems, are important for the passage of certain molecules into cells. Drugs are only carried in this way if they have the necessary specificity of structure, e.g. 5-fluorouracil is transported by a system for endogenous pyrimidines and L-a-methyldopa by an amino-acid carrying system. Placental transport for such drugs has not been studied as far as we are aware, but the specificity of structure required implies that active transport and facilitated diffusion have little general importance in the passage of drugs to the foetus.
Passage Through Membrane Pores
The pores in the lipid membrane are important in determining the permeability of the membrane. It seems probable that the placental pores, like those of the gastrointestinal tract and the bloodbrain barrier, are about IOA (lnm) in diameter and that only molecules with a molecular weight of less than 100, e.g. urea, will pass through. Few drugs are in this category.
Pinocytosis
Pinocytosis is important for the passage of very small quantities of macromolecules through membranes. Although significant for the entry of viruses and immunologically active substances into the foetal circulation, the scale of transfer is too small to be an important route to the foetus for drugs.
